Pulse Biosciences, Inc. reported $1.2M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.2M (to Q2 2026). Net income: −$80M, trailing twelve months to Q2 2026. Free cash flow: −$61M, trailing twelve months to Q2 2026. Operating margin: −10299%, trailing twelve months to Q2 2026.

PLSEPulse Biosciences, Inc.

Healthcare

$53.80+206% 1Y

$53.80

$12.6652 weeks$55.20

PLSE as reported

Pulse Biosciences, Inc. reported $1.2M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed.

$1.2M

Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied

Net income: −$80M
Net income · +18% year on year · trailing twelve months to Q2 2026
Free cash flow: −$61M
Free cash flow · +37% year on year · trailing twelve months to Q2 2026
Operating margin: −10299%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PLSE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.2M	n/a	Q2 2026
Net income	−$80M	+18%	Q2 2026
EPS	−$2.03	n/a	Q3 2022 · 15 quarters behind
Gross margin	−45%	n/a	Q2 2026
Operating margin	−10299%	n/a	Q2 2026
Net margin	−9865%	n/a	Q2 2026
ROE	−91%	n/a	Q2 2026
ROA	−77%	n/a	Q2 2026
ROIC	171162%	n/a	Q4 2023 · 10 quarters behind
Free cash flow	−$61M	+37%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.